ZEISS MyoCare Portfolio: Efficacy Confirmed in Asian and Caucasian Children

Aalen, Germany | 7 May 2024 | ZEISS Vision Care

In ongoing multi-center trials across Asia and Europe, lenses from the ZEISS MyoCare portfolio are seen to significantly slow progression of myopia as compared to single vision lenses.

• Meeting the need for robust evaluation
• Slower myopia progression observed in Asian and Caucasian children
• Emmetropic progression ratio
• Overview clinical trials
• About ZEISS MyoCare lenses and related scientific efforts

The rising global prevalence of myopia is accompanied by a growing burden. (1) Therefore, it is imperative to develop effective solutions to manage myopia. ZEISS has been at the forefront of myopia management for decades and with the latest ZEISS MyoCare portfolio, ZEISS establishes a robust body of evidence for the efficacy of the ZEISS MyoCare portfolio in human trials involving large samples, different ethnicities, and multiple research locations.

At the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2024 ZEISS Vision Care presented these latest study results from ongoing multi-center trials in Asia and Europe. The posters presented at ARVO can be found here and include 12-month results for a multi-center trial in China, and 6-month results for a multi-center trial from Spain and Portugal.

The ZEISS MyoCare lenses significantly slowed myopia progression in both Asian and Caucasian children compared to ZEISS single vision lenses: In Asian children, after twelve months of wear, ZEISS MyoCare slowed myopia progression on average by 0.31 D and 0.13 mm (relative efficacy of 48% and 41%) and ZEISS MyoCare S lenses slowed myopia progression on average by 0.29 D and 0.11 mm (relative efficacy of 45% and 34%, respectively). (2) Additionally, both lenses reduced the risk of fast progression (≤ -0.75 D or more per year). (3) In Caucasian children, compared to ZEISS single vision lenses, use of ZEISS MyoCare lenses for six months resulted in a reduction of myopia progression by an average of 0.15 D and 0.07 mm (relative efficacy of 63% and 77%). (4)

In both groups, vision with ZEISS MyoCare lenses was rated to be either good or very good, and the daily wear time did not differ from regular single vision lenses. (5; 6)

Axial elongation when using ZEISS MyoCare and ZEISS MyoCare S lenses was compared to physiological axial elongation in emmetropic eyes and reported as emmetropic progression ratio (EPR). For Asian children, on average EPRs of 70%* for ZEISS MyoCare and 68% for ZEISS MyoCare S were seen after twelve months of wear. (7)

The published results are derived from two distinct multi-center clinical trials, the first of which is conducted at three locations in China (Tianjin, Shenyang and Beijing) with 240 Chinese children aged six to 13 years, spherical equivalent refractive error (SE) of -0.75 D to -5.00 D, randomly assigned to ZEISS single vision lenses, ZEISS MyoCare, or ZEISS MyoCare S lenses (80 children per group). Results for the first twelve months of this on-going trial were reported at ARVO. 

The second multi-center trial involves 304 Caucasian children, six to 13 years of age, SE of -0.75 D to -5.00 D and past annual progression of at least -0.50 D. This study is being conducted with ISEC Lisboa, Portugal, and Complutense University of Madrid, Spain, at six clinics. Children in the trial are randomly assigned to either ZEISS single vision lenses (N = 152) or ZEISS MyoCare lenses (N = 152). Results for the first six months of wear were reported at ARVO.

^{(1) Holden, Fricke, Wilson, Jong, Naidoo, Sankaridurg et al. Ophthalmology, 2016 123(5):1036-42.
(2) The relative efficacy describes the reduction of progression compared to the control group wearing ZEISS single vision lenses. / Chen, X., et al. (2024, May 5-9). Slowing myopia progression with cylindrical annular refractive elements (CARE) – 12-month interim results from a 2-year prospective multi-center trial [Conference presentation abstract]. The Association for Research in Vision and Opthalmology (ARVO) Annual Meeting, Seattle, WA, United States.
(3) Sankaridurg, P., et al. (2024, May 5-9). Probability of surviving fast progression and eye growth reversal after 1-year of spectacle wear with cylindrical annular refractive elements [Conference presentation abstract]. The Association for Research in Vision and Opthalmology (ARVO) Annual Meeting, Seattle, WA, United States.
(4) Alvarez-Peregrina, C., et al. (2024, May 5-9). Efficacy of a next-generation design of ophthalmic lenses for myopia control: Six-month results of the CEME Study [Conference presentation abstract]. The Association for Research in Vision and Opthalmology (ARVO) Annual Meeting, Seattle, WA, United States.
(5) Alvarez-Peregrina C., et al. (2024, April 12-14). Vision, confort y tiempo de adaptacion a un nuevo diseno de lente oftalmica para el control de miopia [Conference presentation abstract]. OPTOM 2024, Madrid, Spain.
(6) Rifai, K., et al. (2024, May 5-9). Subjective acceptance of spectacle lenses with cylindrical annular refractive elements (CARE) in Chinese children with myopia [Conference presentation abstract]. The Association for Research in Vision and Opthalmology (ARVO) Annual Meeting, Seattle, WA, United States.
(7) Emmetropic Progression Ratio (EPR) on a scale of 0 – 100%, where 0% equals axial elongation equivalent to a myopic eye and 100% equals axial elongation equivalent to an emmetropic eye. / Ohlendorf, A., et al. (2024, May 5-9). Myopia control efficacy through Emmetropic Progression Ratio:1-year of spectacle wear with cylindrical annular refractive elements (CARE) [Conference presentation abstract]. The Association for Research in Vision and Opthalmology (ARVO) Annual Meeting, Seattle, WA, United States.
* EPR for ages 7-12 yr old children as sample size for ages 6 and 13 was small. When the entire sample of 6 to 13 years were considered, EPR for ZEISS MyoCare was 71%.}